Accendra Health, Inc. filed a Form 8-K on October 30, 2026, disclosing that it received a notice from the New York Stock Exchange on October 27, 2026, stating the company is not in compliance with the NYSE's continued listing standard under Section 802.01B of the NYSE Listed Company Manual.

Key Highlights

  • NYSE noncompliance notice: Accendra Health received a notice from the NYSE on October 27, 2026, citing failure to meet the continued listing standard in Section 802.01B.
  • Listing standard at issue: Section 802.01B requires an average market capitalization of not less than $50.0 million over a consecutive 30 trading-day period and stockholders' equity of not less than $50.0 million.
  • No immediate listing impact: According to the filing, "The Notice has no immediate impact on the listing of the Common Stock on the NYSE, subject to the Company's compliance with the NYSE's other continued listing requirements."
  • 45-day window to submit a plan: The company has 45 calendar days following receipt of the notice to submit a business plan demonstrating how it intends to regain compliance within 18 months of receipt of the notice.
  • Intent to notify NYSE: The company disclosed it intends to notify the NYSE within 10 business days of receipt of the notice of its intent to submit a business plan.
  • Operations and SEC obligations unaffected: The filing states "The Notice does not affect the Company's business operations or its reporting obligations with the Securities and Exchange Commission."

Accendra Health Discloses NYSE Section 802.01B Noncompliance and Path to Cure

Accendra Health, Inc. (NYSE:ACH), a Virginia-incorporated company headquartered at 4435 Waterfront Drive, Suite 300, Glen Allen, Virginia, disclosed in an 8-K filed October 30, 2026, that it received a noncompliance notice from the NYSE on October 27, 2026. The notice cited Section 802.01B of the NYSE Listed Company Manual, which sets a minimum average market capitalization of not less than $50.0 million over a consecutive 30 trading-day period combined with stockholders' equity of not less than $50.0 million. The filing does not specify the company's actual market capitalization or stockholders' equity figures.

According to the filing, the notice carries no immediate effect on the listing of the company's Common Stock on the NYSE, provided the company continues to meet the exchange's other continued listing requirements. The company disclosed it is considering "a number of available alternatives to cure its non-compliance with the applicable criteria." Under the timeline set out in the notice, the company has 45 calendar days to submit a business plan showing how it plans to return to compliance within 18 months of receiving the notice. If the NYSE accepts the plan, the company will be subject to quarterly monitoring of that plan's progress.

The company also stated it intends to notify the NYSE of its intent to submit a business plan within 10 business days of receipt of the notice. A press release dated October 30, 2026, was furnished as Exhibit 99.1 to the filing under Item 7.01 (Regulation FD Disclosure). The 8-K was signed by Jonathan A. Leon, Executive Vice President and Chief Financial Officer, on October 30, 2026.

What Was Disclosed

Accendra Health filed an 8-K reporting a NYSE noncompliance notice received October 27, 2026, under Section 802.01B related to minimum market capitalization and stockholders' equity thresholds. The company has 45 calendar days to submit a remediation business plan and stated the notice does not affect operations or SEC reporting obligations.